KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Goodwill (2017 - 2025)

Historic Goodwill for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $595.9 million.

  • Amneal Pharmaceuticals' Goodwill fell 39.76% to $595.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.9 million, marking a year-over-year decrease of 39.76%. This contributed to the annual value of $597.4 million for FY2024, which is 19.93% down from last year.
  • Amneal Pharmaceuticals' Goodwill amounted to $595.9 million in Q3 2025, which was down 39.76% from $597.4 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Goodwill ranged from a high of $602.9 million in Q1 2022 and a low of $522.8 million during Q1 2021
  • For the 5-year period, Amneal Pharmaceuticals' Goodwill averaged around $590.1 million, with its median value being $598.5 million (2024).
  • In the last 5 years, Amneal Pharmaceuticals' Goodwill skyrocketed by 1532.93% in 2022 and then tumbled by 61.98% in 2023.
  • Amneal Pharmaceuticals' Goodwill (Quarter) stood at $593.0 million in 2021, then rose by 0.98% to $598.9 million in 2022, then fell by 0.04% to $598.6 million in 2023, then dropped by 0.2% to $597.4 million in 2024, then dropped by 0.25% to $595.9 million in 2025.
  • Its Goodwill stands at $595.9 million for Q3 2025, versus $597.4 million for Q2 2025 and $597.5 million for Q1 2025.